Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell Sells 25,000 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the transaction, the chief executive officer now owns 217,054 shares in the company, valued at approximately $12,196,264.26. This trade represents a 10.33 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

David Alan Campbell also recently made the following trade(s):

• On Tuesday, December 3rd, David Alan Campbell sold 15,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $67.00, for a total transaction of $1,005,000.00.
• On Monday, November 25th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The stock was sold at an average price of $51.60, for a total transaction of $1,290,000.00.
• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $53.54, for a total value of $1,338,500.00.

Janux Therapeutics Trading Down 1.9 %

Shares of JANX stock opened at $54.10 on Monday. Janux Therapeutics, Inc. has a 12-month low of $7.79 and a 12-month high of $71.71. The business’s 50 day moving average is $54.43 and its two-hundred day moving average is $47.50. The company has a market capitalization of $2.84 billion, a P/E ratio of -46.24 and a beta of 3.29.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The business had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company’s revenue for the quarter was down 82.6% on a year-over-year basis. On average, research analysts predict that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Leerink Partners increased their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. UBS Group initiated coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $69.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $200.00 target price on shares of Janux Therapeutics in a report on Wednesday, December 11th. Finally, William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics has an average rating of “Buy” and a consensus price target of $89.90.

Institutional Trading of Janux Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of JANX. Charles Schwab Investment Management Inc. boosted its holdings in Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after buying an additional 156,675 shares during the last quarter. Ally Bridge Group NY LLC purchased a new position in shares of Janux Therapeutics in the third quarter valued at approximately $4,943,000. Algert Global LLC acquired a new stake in shares of Janux Therapeutics in the third quarter worth approximately $1,112,000. FMR LLC increased its position in shares of Janux Therapeutics by 0.6% during the third quarter. FMR LLC now owns 7,824,675 shares of the company’s stock worth $355,475,000 after purchasing an additional 47,075 shares in the last quarter. Finally, Neo Ivy Capital Management acquired a new position in Janux Therapeutics in the 3rd quarter valued at $940,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.